Childhood Cancer Awareness Month: connecting science to advance better treatments

Childhood cancers differ biologically from cancers in adults. Developing better treatments requires research that addresses these differences and brings together complementary evidence to guide development.

Three closely connected questions help shape this work: Is a therapeutic target relevant in childhood cancers? Does a particular drug show promising activity in appropriate preclinical models? And how should these findings inform clinical development in light of patients’ needs?

Answering these questions requires molecular insights into paediatric tumours, robust experimental evaluation and clinical interpretation. Each contributes a different perspective. Their value lies in bringing them together to identify which approaches warrant further investigation, what evidence is still needed and how to move forward.

At ITCC-P4, we contribute to this shared effort through scientific advice for preclinical development planning and studies conducted with our three partner CROs. Working with academic and industry partners, we help assess the biological rationale, define relevant research questions, design studies and interpret their findings in the broader context of paediatric drug development.

The publication of the ITCC-P4 consortium’s main study in Cancer Research this July marks an important milestone. It illustrates how molecularly characterised patient-derived tumour models can support the evaluation and prioritisation of potential new therapies.

Behind this progress are patients and families, researchers, clinicians and partners working towards a common goal. As a non-profit organisation, ITCC-P4 is committed to helping translate their shared efforts into evidence that advances better treatment options for young patients.

Contact us to explore how ITCC-P4 can support your research or preclinical development programme!